Journal of Immunology Research / 2017 / Article / Fig 6

Research Article

Synergistic Antitumour Properties of viscumTT in Alveolar Rhabdomyosarcoma

Figure 6

viscumTT effectively reduces tumour volume in patient-derived RMS xenografts. Patient-derived RMS cells from (a) patient no. 1 and (b) patient no. 2 were used for s.c. implantation in the inguinal region of mice. Treatment started on day 12 when tumours were palpable, with (a) i.t. administration of viscum, TT, viscumTT, cyclodextrins (CD; control group), and i.v. doxorubicin (Doxo) and (b) i.t. administration of viscumTT and i.v. treatment with viscumTT and cyclodextrins. The mice were treated every two-three days in rising concentrations, and each dose was given twice. The administered concentrations were 40/60/80 mg/kg oleanolic acid (TT), 0.5/1.0/1.5 μg/kg mistletoe lectin (viscum), or a combination thereof (viscumTT). Two-way ANOVA and Bonferroni post hoc tests were applied to determine differences between mouse xenograft treatment groups ().
(a)
(b)

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.